Bausch Health Cos Inc. $BHC Holdings Reduced by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership decreased its holdings in Bausch Health Cos Inc. (NYSE:BHC) by 59.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,759,951 shares of the company’s stock after selling 2,564,275 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.48% of Bausch Health Cos worth $11,739,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nomura Holdings Inc. lifted its stake in shares of Bausch Health Cos by 106.2% in the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock worth $151,366,000 after acquiring an additional 12,050,000 shares during the period. MUFG Securities EMEA plc bought a new stake in Bausch Health Cos during the second quarter worth approximately $22,644,000. SG Americas Securities LLC lifted its position in Bausch Health Cos by 114.4% in the second quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after purchasing an additional 3,282,684 shares during the period. Acadian Asset Management LLC boosted its stake in Bausch Health Cos by 4,134.7% during the 1st quarter. Acadian Asset Management LLC now owns 673,316 shares of the company’s stock valued at $4,347,000 after purchasing an additional 657,416 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Bausch Health Cos by 97.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after purchasing an additional 467,270 shares during the period. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Price Performance

NYSE BHC opened at $6.80 on Wednesday. The company has a debt-to-equity ratio of 57.48, a current ratio of 1.30 and a quick ratio of 0.97. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of 7.01 and a beta of 0.41. The company has a 50 day simple moving average of $6.45 and a 200-day simple moving average of $6.45. Bausch Health Cos Inc. has a 52-week low of $4.25 and a 52-week high of $8.69.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BHC shares. Weiss Ratings restated a “hold (c-)” rating on shares of Bausch Health Cos in a research report on Monday. Barclays began coverage on shares of Bausch Health Cos in a research note on Monday. They set an “equal weight” rating and a $8.00 target price for the company. Finally, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Bausch Health Cos currently has a consensus rating of “Hold” and a consensus target price of $8.67.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.